BioCentury
ARTICLE | Clinical News

RG-201 dicationic compound that appears to bind to the topoisomerase of Pneumocystis carinii pneumonia: Will start Phase I trial in a couple of months. The firs

June 19, 1995 7:00 AM UTC

RiboGene Inc., Hayward, Calif. Product: RG-201 dicationic compound that appears to bind to the topoisomerase of Pneumocystis carinii pneumonia (PCP) bacteria and not to the mammalian molecule Indicat...